WO2010125572A1 - Compressed tablets and capsules containing efavirenz - Google Patents
Compressed tablets and capsules containing efavirenz Download PDFInfo
- Publication number
- WO2010125572A1 WO2010125572A1 PCT/IN2009/000259 IN2009000259W WO2010125572A1 WO 2010125572 A1 WO2010125572 A1 WO 2010125572A1 IN 2009000259 W IN2009000259 W IN 2009000259W WO 2010125572 A1 WO2010125572 A1 WO 2010125572A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compressed tablet
- capsule
- efavirenz
- sodium
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
Definitions
- the present invention provides improved oral dosage form formulations of efavirenz useful in the prevention or treatment of infection by HIV.
- HIV reverse transcriptase (including its resistant varieties) inhibitors are described in U.S. Patent No. 5,519,021.
- An especially important compound among those disclosed is efavirenz, (4S)-6- chloro-4-(cyclopropylethynyl)-1 ,4-dihydro-4-(trifluoromethyl)-2H-3, 1 -benzoxazin- 2-one.
- Efavirenz is used for the preparation of a medicament having nonnucleoside HIV-1 reverse transcriptase inhibiting activity that is useful in the prevention or treatment of infection by HIV and the treatment of AIDS.
- Efavirenz is sold commercially as SUSTIVA® by Bristol Myers Squibb.
- 1 ,4-di hydro-2H-3,1-benzoxazin-2-one including: 1) a process for making the chiral alcohol, U.S. Ser. No. 60/035,462, filed Jan. 14, 1997; 2) the chiral additive, U.S. Ser. No. 60/034,926, filed Jan. 10, 1997; 3) the cyclization reaction, U.S. Ser. No. 60/037,059, filed Feb. 12, 1997; and the anti-solvent crystallization procedure, U.S. Ser. No. 60/037,385 filed Feb. 5, 1997 and U.S.
- WO patent application publication No. 98/33782 discloses three crystalline forms, Form I, Form Il and Form III of efavirenz.
- WO patent application publication No. 99/64405 discloses five crystalline forms, Form 1 , Form 2, Form 3, Form 4 and Form 5 of efavirenz.
- U. S Patent No. 6,555,133 discloses the method for treating infection by HIV comprising administrating to a patient in need of such treatment, a capsule or a compressed tablet pharmaceutical dosage form comprising a therapeutically effective amount of efavirenz and greater than about 10% by weight of disintegrant relative to the total dry weight of the pharmaceutical dosage form.
- Disintegrant is selected from modified starches, croscarmellose sodium, carboxy methyl cellulose calcium and crospovidone.
- U. S Patent No. 7060294B2 discloses the manufacturing of the solid dosage form of efavirenz, which mainly comprises efavirenz, filler, disintegrant, super disintegrant, binder, surfactant, filler/compression aid, lubricants and solvents, where in efavirenz is about 50% by weight of total composition of the compressed tablet between about 1.0 % to about 5.0 % by weight of super disintegrant and the super disintegrant is croscarmellose sodium.
- WO Patent Application Publication No. WO 2006/018853 discloses synthesis of a novel crystalline and amorphous form of efavirenz i.e.
- efavirenz Form H1 and the novel crystalline efavirenz form H1 is characterized by an x-ray powder diffraction spectrum having peaks expressed as 29 at about 5.4, 10.4, 11.6, 12.5, 15.3, 20.1 , 20.8, 22.5, 23.1, 25.7, 27.9, 28.5, 28.8, 29.5, 30.2 and 38.2 degrees.
- This invention relates to solid oral dosage form formulations containing the HIV drug efavirenz that enhance the dissolution rate in the gastrointestinal tract in order to improve the rate and extent of absorption into the body, thereby improving its therapeutic effect.
- the compressed tablet formulation includes efavirenz, super disintegrant, diluent/filler, glidant, lubricant and optionally film coated.
- a pharmaceutical composition which comprises a compressed tablet or a capsule wherein therapeutic ingredient efavirenz is present about 10 to 50% by weight of the total composition of the compressed tablet or a capsule and one or more superdisintegrant in the concentration of about 5.0 to 10.0% by weight relative to the total weight of the compressed tablet or a capsule wherein said superdisintegrant is selected from the group consisting of crospovidone, sodium starch glycolate and croscarmellose sodium.
- Preferable efavirenz is present about 30 to 46 % by weight of the total composition of the compressed tablet or a capsule.
- More preferable efavirenz is present about 40 to 46% by weight relative to the total weight of the compressed tablet or a capsule.
- the pharmaceutical composition may also contain one or more other active ingredients such as emitricitabine, tenofovir disoproxil fumarate.
- Preferable superdisintegrant is selected from the group consisting of crospovidone and sodium starch glycolate. More preferable the superdisintegrant is crospovidone. Preferable the superdisintegrant is in the concentration of about 6.0 to
- the superdisintegrant is in the concentration of about 7.0 to 8.5%.
- efavirenz is more than 50% by weight of the total composition of the compressed tablet or a capsule with a superdisintegrant concentration of 5.0% to 10.0% by weight relative to total weight of the compressed tablet or capsule, the rate of dissolution is decreased compared to efavirenz when present about 10% to 50% by weight of the total composition of the compressed tablet or a capsule with the same concentration of a superdisintegrant.
- efavirenz is preferably efavirenz form H1.
- Disintegrants are substances or a mixture of substances added to a formulation to facilitate the breakup or disintegration of the solid dosage form after administration.
- Materials that serve as disintegrants include starches, clays, celluloses, algins, gums and cross-linked polymers.
- a group of disintegrants referred to as "super-disintegrants” generally are used at a low level in the solid dosage form.
- Crospovidone, croscarmellose, and sodium starch glycolate represent examples of cross-linked cellulose, a cross-linked polymer and a cross-linked starch, respectively.
- the pharmaceutical composition of compressed tablet or a capsule of the invention may contain one or more additional excipients. These excipients include among others, diluents, disintegrant, surfactants, lubricants and glidants.
- the preferable diluent is selected from the group consisting of mannitol, sorbitol, starch, modified starches, xylitol, lactose, microcrystalline cellulose, magnesium carbonate, starch, calcium carbonate, dicalcium phosphate, tribasic calcium phosphate, and calcium sulphate.
- the more preferable diluent is selected from the group consisting of microcrystalline cellulose and lactose.
- the preferable surfactant is selected from the group consisting of sodium lauryl sulfate, docusate sodium, benzekonium chloride, benzethonium chloride and cetrimide.
- the more preferable surfactant is selected from the group consisting of sodium lauryl sulfate.
- the preferable glidants are talc, colloidal silicon dioxide, asbestos free talc, sodium aluminosilicate, calcium silicate, powdered cellulose, sodium benzoate and magnesium lauryl sulfate, magnesium oxide. More preferably glidant is colloidal silicon dioxide.
- Lubricants are magnesium stearate, zinc stearate, calcium stearate, sodium lauryl sulfate and sodium stearyl fumarate. More preferably lubricant is magnesium stearate.
- efavirenz is preferably present an amount of from 200 mg to about 600 mg in a single dosage unit.
- the pharmaceutical composition does not contain a binder.
- a process for preparing pharmaceutical composition of compressed tablet or a capsule of efavirenz which comprises wet granulation of efavirenz, disintegrants selected from the group consisting of crospovidone, sodium starch glycolate and croscarmellose sodium and other excipients in the presence of aqueous solution of sodium lauryl sulfate, drying, dry blending and lubricating with pharmaceutically acceptable ingredients and compressed into tablets or filled in capsules said process is characterized in that the process does not involve milling and said drying step is carried out at 25°C-45°C. Preferably the drying step is carried out at 30 0 C to 40 0 C.
- Efavirenz is mixed with other ingredients and then wet granulated using an aqueous solution of sodium lauryl sulfate. This wet mass may then be dried in a fluid bed, tray or other suitable dryer. The dried granules are blended and lubricated. This blend is compressed into tablets. The compressed tablets are film coated.
- Method of manufacture The method of manufacturing process is same as that described in Example.1.
- the tablets are coated using the same composition as the coating composition of Example.1.
- Method of manufacture The method of manufacturing process is same as that described in Example.1.
- the tablets are coated using the same composition as the coating composition of Example.1.
- Method of manufacture The method of manufacturing process is same as that described in Example.1.
- the tablets are coated using the same composition as the coating composition of Example.1.
- Efavirenz is mixed with other ingredients and then wet granulated using an aqueous solution of sodium lauryl sulfate. This wet mass may then be dried in a fluid bed, tray or other suitable dryer. The dried granules are blended and lubricated. Emitricitabine and tenofovir disproxil fumarate is compacted with other excipients and lubricated. Emitricitabine, tenofovir disproxil fumarate final blend and efavirenz final blend are lubricated together with magnesium stearate and colloidal silicon dioxide and mixed together. This blend is compressed into tablets. The compressed tablets are film coated using the coating composition mentioned in example 6.
- composition contains efavirenz more than 50% by weight of the total composition of the compressed tablet or a capsule with a superdisintegrant concentration of 5.0% to 10.0% by weight relative to total weight of the compressed tablet or capsule.
- 600 mg tablet formulation 600 mg tablet formulation:
- Method of manufacture The method of manufacturing process is same as that described in Example.1.
- the tablets are coated using the same composition as the coating composition of Example.1.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides improved oral dosage form formulations of efavirenz useful in the prevention or treatment of infection by HIV and the process for preparing them. Thus, for example the improved oral dosage form of efavirenz which is prepared by wet granulating efavirenz, a disintegrant and other excipients in the presence of aqueous solution of sodium lauryl sulfate, drying the granules at a temperature of about 25°C to 45°C, dry blending, lubricating with pharmaceutically acceptable ingredients and compressed into tablets or filled in capsules.
Description
COMPRESSED TABLETS AND CAPSULES CONTAINING EFAVIRENZ
FIELD OF THE INVENTION
The present invention provides improved oral dosage form formulations of efavirenz useful in the prevention or treatment of infection by HIV.
BACKGROUND OF THE INVENTION
Pharmaceutical products with HIV reverse transcriptase (including its resistant varieties) inhibitors are described in U.S. Patent No. 5,519,021. An especially important compound among those disclosed is efavirenz, (4S)-6- chloro-4-(cyclopropylethynyl)-1 ,4-dihydro-4-(trifluoromethyl)-2H-3, 1 -benzoxazin- 2-one.
Efavirenz is used for the preparation of a medicament having nonnucleoside HIV-1 reverse transcriptase inhibiting activity that is useful in the prevention or treatment of infection by HIV and the treatment of AIDS. Efavirenz is sold commercially as SUSTIVA® by Bristol Myers Squibb.
The synthesis of efavirenz and structurally similar reverse transcriptase inhibitors are disclosed in U.S. Pat. No's. 5519021 , 5663169 and 5665720.
Additionally, several applications have been filed which disclose various aspects of the synthesis of (-)6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-
1 ,4-di hydro-2H-3,1-benzoxazin-2-one including: 1) a process for making the chiral alcohol, U.S. Ser. No. 60/035,462, filed Jan. 14, 1997; 2) the chiral additive, U.S. Ser. No. 60/034,926, filed Jan. 10, 1997; 3) the cyclization reaction, U.S. Ser. No. 60/037,059, filed Feb. 12, 1997; and the anti-solvent crystallization procedure, U.S. Ser. No. 60/037,385 filed Feb. 5, 1997 and U.S.
Ser. No. 60/042,807 filed Apr. 8, 1997.
WO patent application publication No. 98/33782 discloses three crystalline forms, Form I, Form Il and Form III of efavirenz.
WO patent application publication No. 99/64405 discloses five crystalline forms, Form 1 , Form 2, Form 3, Form 4 and Form 5 of efavirenz.
U. S Patent No. 6,555,133 discloses the method for treating infection by HIV comprising administrating to a patient in need of such treatment, a capsule or a compressed tablet pharmaceutical dosage form comprising a therapeutically effective amount of efavirenz and greater than about 10% by
weight of disintegrant relative to the total dry weight of the pharmaceutical dosage form. Disintegrant is selected from modified starches, croscarmellose sodium, carboxy methyl cellulose calcium and crospovidone.
U. S Patent No. 7060294B2 discloses the manufacturing of the solid dosage form of efavirenz, which mainly comprises efavirenz, filler, disintegrant, super disintegrant, binder, surfactant, filler/compression aid, lubricants and solvents, where in efavirenz is about 50% by weight of total composition of the compressed tablet between about 1.0 % to about 5.0 % by weight of super disintegrant and the super disintegrant is croscarmellose sodium. WO Patent Application Publication No. WO 2006/018853 discloses synthesis of a novel crystalline and amorphous form of efavirenz i.e. efavirenz Form H1 and the novel crystalline efavirenz form H1 is characterized by an x-ray powder diffraction spectrum having peaks expressed as 29 at about 5.4, 10.4, 11.6, 12.5, 15.3, 20.1 , 20.8, 22.5, 23.1, 25.7, 27.9, 28.5, 28.8, 29.5, 30.2 and 38.2 degrees.
This invention relates to solid oral dosage form formulations containing the HIV drug efavirenz that enhance the dissolution rate in the gastrointestinal tract in order to improve the rate and extent of absorption into the body, thereby improving its therapeutic effect. The compressed tablet formulation includes efavirenz, super disintegrant, diluent/filler, glidant, lubricant and optionally film coated.
Therefore, taking into account the great therapeutic interest of efavirenz, there still exists a need in the state of the art for new pharmaceutical dosage forms of efavirenz.
DETAILED DESCRIPTION OF THE INVENTION According to one aspect of the present invention there is provided a pharmaceutical composition which comprises a compressed tablet or a capsule wherein therapeutic ingredient efavirenz is present about 10 to 50% by weight of the total composition of the compressed tablet or a capsule and one or more superdisintegrant in the concentration of about 5.0 to 10.0% by weight relative to the total weight of the compressed tablet or a capsule wherein said superdisintegrant is selected from the group consisting of crospovidone, sodium starch glycolate and croscarmellose sodium.
Preferable efavirenz is present about 30 to 46 % by weight of the total composition of the compressed tablet or a capsule. More preferable efavirenz is present about 40 to 46% by weight relative to the total weight of the compressed tablet or a capsule. The pharmaceutical composition may also contain one or more other active ingredients such as emitricitabine, tenofovir disoproxil fumarate.
Preferable superdisintegrant is selected from the group consisting of crospovidone and sodium starch glycolate. More preferable the superdisintegrant is crospovidone. Preferable the superdisintegrant is in the concentration of about 6.0 to
8.5%. More preferable the superdisintegrant is in the concentration of about 7.0 to 8.5%.
It has been found that if efavirenz is more than 50% by weight of the total composition of the compressed tablet or a capsule with a superdisintegrant concentration of 5.0% to 10.0% by weight relative to total weight of the compressed tablet or capsule, the rate of dissolution is decreased compared to efavirenz when present about 10% to 50% by weight of the total composition of the compressed tablet or a capsule with the same concentration of a superdisintegrant. Another embodiment of the present invention, wherein efavirenz is preferably efavirenz form H1.
Disintegrants are substances or a mixture of substances added to a formulation to facilitate the breakup or disintegration of the solid dosage form after administration. Materials that serve as disintegrants include starches, clays, celluloses, algins, gums and cross-linked polymers. A group of disintegrants referred to as "super-disintegrants" generally are used at a low level in the solid dosage form. Crospovidone, croscarmellose, and sodium starch glycolate represent examples of cross-linked cellulose, a cross-linked polymer and a cross-linked starch, respectively. The pharmaceutical composition of compressed tablet or a capsule of the invention may contain one or more additional excipients. These excipients include among others, diluents, disintegrant, surfactants, lubricants and glidants.
The preferable diluent is selected from the group consisting of mannitol, sorbitol, starch, modified starches, xylitol, lactose, microcrystalline cellulose,
magnesium carbonate, starch, calcium carbonate, dicalcium phosphate, tribasic calcium phosphate, and calcium sulphate. The more preferable diluent is selected from the group consisting of microcrystalline cellulose and lactose.
The preferable surfactant is selected from the group consisting of sodium lauryl sulfate, docusate sodium, benzekonium chloride, benzethonium chloride and cetrimide. The more preferable surfactant is selected from the group consisting of sodium lauryl sulfate.
The preferable glidants are talc, colloidal silicon dioxide, asbestos free talc, sodium aluminosilicate, calcium silicate, powdered cellulose, sodium benzoate and magnesium lauryl sulfate, magnesium oxide. More preferably glidant is colloidal silicon dioxide.
The preferable Lubricants are magnesium stearate, zinc stearate, calcium stearate, sodium lauryl sulfate and sodium stearyl fumarate. More preferably lubricant is magnesium stearate. In the pharmaceutical composition of compressed tablet or a capsule of the invention efavirenz is preferably present an amount of from 200 mg to about 600 mg in a single dosage unit.
In an embodiment of the present invention, the pharmaceutical composition does not contain a binder. According to another aspect of the present invention there is provided a process for preparing pharmaceutical composition of compressed tablet or a capsule of efavirenz which comprises wet granulation of efavirenz, disintegrants selected from the group consisting of crospovidone, sodium starch glycolate and croscarmellose sodium and other excipients in the presence of aqueous solution of sodium lauryl sulfate, drying, dry blending and lubricating with pharmaceutically acceptable ingredients and compressed into tablets or filled in capsules said process is characterized in that the process does not involve milling and said drying step is carried out at 25°C-45°C. Preferably the drying step is carried out at 300C to 400C.
Examples
Example 1
600 mg tablet formulation:
Method of manufacture: Efavirenz is mixed with other ingredients and then wet granulated using an aqueous solution of sodium lauryl sulfate. This wet mass may then be dried in a fluid bed, tray or other suitable dryer. The dried granules are blended and lubricated. This blend is compressed into tablets. The compressed tablets are film coated.
Example-2
600 mg tablet formulation:
Method of manufacture: The method of manufacturing process is same as that described in Example.1. The tablets are coated using the same composition as the coating composition of Example.1.
Example-3
600 mg tablet formulation:
Method of manufacture: The method of manufacturing process is same as that described in Example.1. The tablets are coated using the same composition as the coating composition of Example.1.
Assay was performed on tablet samples taken during the manufacturing processes described above. Analysis of the capsules and tablets utilized USP specified procedures. The dissolution test using USP methodology apparatus 2 (Paddle at 50 RPM, 1000 ml of 2.0 % sodium lauryl sulfate-distilled water solution).
Dissolution assay of Tablet Formulation Table 1 : Tablet Formulation of Example 3:
Table 1
Example-4
600 mg tablet formulation:
Method of manufacture: The method of manufacturing process is same as that described in Example.1. The tablets are coated using the same composition as the coating composition of Example.1.
Example-5 200 mg capsule formulation:
Example-6
Method of manufacture: Efavirenz is mixed with other ingredients and then wet granulated using an aqueous solution of sodium lauryl sulfate. This wet mass may then be dried in a fluid bed, tray or other suitable dryer. The dried granules are blended and lubricated. Emitricitabine and tenofovir disproxil fumarate is compacted with other excipients and lubricated. Emitricitabine, tenofovir disproxil fumarate final blend and efavirenz final blend are lubricated together with magnesium stearate and colloidal silicon dioxide and mixed together. This blend is compressed into tablets. The compressed tablets are film coated using the coating composition mentioned in example 6.
Comparative Example:
The following composition contains efavirenz more than 50% by weight of the total composition of the compressed tablet or a capsule with a superdisintegrant concentration of 5.0% to 10.0% by weight relative to total weight of the compressed tablet or capsule. 600 mg tablet formulation:
Assay was performed on tablet samples taken during the manufacturing processes described above. Analysis of the capsules and tablets utilized USP specified procedures. The dissolution test using USP methodology apparatus 2 (Paddle at 50 RPM, 1000 ml of 2.0 % sodium lauryl sulfate-distilled water solution).
Dissolution assay of Tablet Formulation Table 2:
Claims
1. The pharmaceutical composition which comprising a) a compressed tablet or a capsule wherein therapeutic ingredient efavirenz is present about 10 to 50% by weight of the total composition of the compressed tablet or capsule and b) one or more superdisintegrant in the concentration of about 5.0 to 10.0% by weight relative to the total weight of the compressed tablet or capsule; wherein, said superdisintegrant is selected from the group consisting of crospovidone, sodium starch glycolate and croscarmellose sodium.
2. The compressed tablet or capsule according to claim 1 , wherein efavirenz is present about 30 to 46 % by weight of the total composition of the compressed tablet or capsule.
3. The compressed tablet or capsule according to claim 1 , wherein the pharmaceutical composition contain one or more other active ingredients such as emitricitabine, tenofovir disoproxil fumarate.
4. The compressed tablet or capsule according to claim 1 , wherein said super disintegrant is selected from the group consisting of crospovidone and sodium starch glycolate.
5. The compressed tablet or capsule according to claim 4, wherein said super disintegrant is crospovidone.
6. The compressed tablet or capsule according to claim 1 , wherein said super disintegrant in an amount of 6.0 to about 8.5% by weight relative to the total weight of the compressed tablet or capsule.
7. The compressed tablet or capsule according to claim 1 , wherein therapeutic ingredient efavirenz is efavirenz form H1.
8. The compressed tablet or capsule according to claim 1 , further comprises one or more additional excipients selected from diluents, surfactants, lubricants and glidants.
9. The compressed tablet or capsule according to claim 8, comprising a diluent is selected from the group consisting of mannitol, sorbitol, xylitol, lactose, microcrystalline cellulose, magnesium carbonate, starch, calcium carbonate, dicalcium phosphate, tribasic calcium phosphate, and calcium sulphate.
10. The compressed tablet or capsule according to claim 9, a diluent is microcrystalline cellulose or Lactose.
1 1. The compressed tablet or capsule according to claim 8, comprising a surfactant selected from the group consisting of sodium lauryl sulfate, docusate sodium, benzekonium chloride, benzethonium chloride and cetrimide.
12. The compressed tablet or capsule according to claim 11 , wherein the surfactant is sodium lauryl sulfate.
13. The compressed tablet or capsule according to claim 11 , wherein the surfactant sodium lauryl sulfate is present in an amount of about 0.1% to about 5% by weight, based on the dry weight of the pharmaceutical dosage form.
14. The compressed tablet or capsule according to claim 1 , where in the composition does not contain a binder.
15. A compressed tablet or capsule according to claim 1 , wherein the efavirenz is present in an amount of from about 200 mg to 600 mg in a single dosage unit.
16. The process for preparing pharmaceutical composition of compressed tablets or a capsule of efavirenz as defined in claim 1 , which comprises wet granulation of efavirenz, disintegrants selected from the group consisting of crospovidone, sodium starch glycolate and croscarmellose sodium and other excipients in the presence of aqueous solution of sodium lauryl sulfate, drying, dry blending and lubricating with pharmaceutically acceptable ingredients and compressed into tablets or filled in capsules said process is characterized in that the process does not involve milling and said drying step is carried out at 25°C-45°C.
17. The process according to claim 16, where in the composition does not contain a binder.
18. The process according to claim 16, where in the wet granules are dried at a temperature in the range of 30°C-40°C.
19. The process according to claim 16, wherein efavirenz is present about 30 to 46% by weight of the total composition of the compressed tablet or capsule.
20. The process according to claim 16, wherein the pharmaceutical composition contain one or more other active ingredients such as emitricitabine, tenofovir disoproxil fumarate.
21. The process according to claim 16, wherein said super disintegrant is selected from the group consisting of crospovidone and sodium starch glycolate.
22. The process according to claim 21 , wherein said super disintegrant is crospovidone.
23. The process according to claim 16, wherein said super disintegrant in an amount of 6.0 to about 8.5% by weight relative to the total weight of the compressed tablet or capsule.
24. The process according to claim 16, wherein therapeutic ingredient efavirenz is efavirenz form H1.
25. The process according to claim 16, wherein additional excipients are diluents, surfactants, lubricants and glidants.
26. The process according to claim 25, comprising a diluent is selected from the group consisting of mannitol, sorbitol, xylitol, lactose, microcrystalline cellulose, magnesium carbonate, starch, calcium carbonate, dicalcium phosphate, tribasic calcium phosphate and calcium sulphate.
27. The process according to claim 26, a diluent is microcrystalline cellulose or lactose.
28. The compressed tablet or capsule according to claim 25, comprising a surfactant selected from the group consisting of sodium iauryl sulfate, docusate sodium, benzekonium chloride, benzethonium chloride and cetrimide.
29. The compressed tablet or capsule according to claim 28, wherein the surfactant is sodium Iauryl sulfate.
30. The process according to claim 28, wherein the surfactant sodium Iauryl sulfate is present in an amount of about 0.1% to about 5% by weight, based on the dry weight of the pharmaceutical dosage form.
31. The process according to claim 25, wherein the efavirenz is present in an amount of from about 200 mg 600 mg in a single dosage unit.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2009/000259 WO2010125572A1 (en) | 2009-04-29 | 2009-04-29 | Compressed tablets and capsules containing efavirenz |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2009/000259 WO2010125572A1 (en) | 2009-04-29 | 2009-04-29 | Compressed tablets and capsules containing efavirenz |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2010125572A1 true WO2010125572A1 (en) | 2010-11-04 |
Family
ID=43031769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2009/000259 WO2010125572A1 (en) | 2009-04-29 | 2009-04-29 | Compressed tablets and capsules containing efavirenz |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2010125572A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110288045A1 (en) * | 2008-11-21 | 2011-11-24 | Ultimorphix Technologies B.V. | Wet granulation of tenofovir, emtricitabine and efavirenz |
| CN102988316A (en) * | 2012-11-22 | 2013-03-27 | 安徽贝克生物制药有限公司 | Efavirenz tablet and preparation method thereof |
| US9498438B2 (en) | 2011-09-09 | 2016-11-22 | The University Of Liverpool | Compositions of efavirenz |
| RU2680967C2 (en) * | 2017-04-11 | 2019-03-01 | Акционерное общество "МираксБиоФарма" | Solid pharmaceutical form of indole-3-carbinol |
| CN114425039A (en) * | 2020-10-29 | 2022-05-03 | 上海迪赛诺药业股份有限公司 | Improved efavirenz quick-release preparation |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6238695B1 (en) * | 1998-04-07 | 2001-05-29 | Dupont Pharmaceuticals Company | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
| US20010014352A1 (en) * | 1998-05-27 | 2001-08-16 | Udit Batra | Compressed tablet formulation |
| WO2006135933A2 (en) * | 2005-06-13 | 2006-12-21 | Bristol-Myers Squibb & Gilead Sciences, Llc | Stable fixed-dose unitary formulations containing tenofovir, a surfactant, efavirenz and emtricitabine |
| WO2006134610A1 (en) * | 2005-06-16 | 2006-12-21 | Hetero Drugs Limited | Efavirenz pharmaceutical composition having enhanced dissolution profile |
| WO2007068934A2 (en) * | 2005-12-14 | 2007-06-21 | Cipla Limited | Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit |
-
2009
- 2009-04-29 WO PCT/IN2009/000259 patent/WO2010125572A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6238695B1 (en) * | 1998-04-07 | 2001-05-29 | Dupont Pharmaceuticals Company | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
| US20010014352A1 (en) * | 1998-05-27 | 2001-08-16 | Udit Batra | Compressed tablet formulation |
| WO2006135933A2 (en) * | 2005-06-13 | 2006-12-21 | Bristol-Myers Squibb & Gilead Sciences, Llc | Stable fixed-dose unitary formulations containing tenofovir, a surfactant, efavirenz and emtricitabine |
| WO2006134610A1 (en) * | 2005-06-16 | 2006-12-21 | Hetero Drugs Limited | Efavirenz pharmaceutical composition having enhanced dissolution profile |
| WO2007068934A2 (en) * | 2005-12-14 | 2007-06-21 | Cipla Limited | Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110288045A1 (en) * | 2008-11-21 | 2011-11-24 | Ultimorphix Technologies B.V. | Wet granulation of tenofovir, emtricitabine and efavirenz |
| US9498438B2 (en) | 2011-09-09 | 2016-11-22 | The University Of Liverpool | Compositions of efavirenz |
| CN102988316A (en) * | 2012-11-22 | 2013-03-27 | 安徽贝克生物制药有限公司 | Efavirenz tablet and preparation method thereof |
| RU2680967C2 (en) * | 2017-04-11 | 2019-03-01 | Акционерное общество "МираксБиоФарма" | Solid pharmaceutical form of indole-3-carbinol |
| CN114425039A (en) * | 2020-10-29 | 2022-05-03 | 上海迪赛诺药业股份有限公司 | Improved efavirenz quick-release preparation |
| CN114425039B (en) * | 2020-10-29 | 2023-12-15 | 上海迪赛诺医药集团股份有限公司 | Improved immediate release formulations of efavirenz |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6238695B1 (en) | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants | |
| EP3009128B1 (en) | Pharmaceutical compositions comprising nilotinib | |
| KR101849808B1 (en) | Preparation for improving solubility of poorly soluble drug | |
| RU2382648C2 (en) | Pharmaceutical composition of carboxamide inhibitors of hiv integrase, containing composition with controlled rate of release | |
| CA2800444C (en) | Ivabradine-containing pharmaceutical composition | |
| US20070104785A1 (en) | Tablets of linezolid form iii and processes for their preparation | |
| JP5283632B2 (en) | Solid pharmaceutical composition containing a benzimidazole-7-carboxylate derivative and a pH adjuster | |
| CA2706292A1 (en) | A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide | |
| WO2010125572A1 (en) | Compressed tablets and capsules containing efavirenz | |
| US8481554B2 (en) | Solid oral dosage forms of lamivudine | |
| WO2006134610A1 (en) | Efavirenz pharmaceutical composition having enhanced dissolution profile | |
| WO2011001440A1 (en) | Pharmaceutical compositions of valsartan | |
| US6514529B2 (en) | Oxazolidinone tablet formulation | |
| JPWO2018230504A1 (en) | Granules, tablets and production method thereof | |
| KR100786410B1 (en) | Oxazolidinone Tablet Formulation | |
| EP3860606A1 (en) | Pharmaceutical composition comprising lenvatinib esylate or tosylate | |
| AU2001243243A1 (en) | Oxazolidinone tablet formulation | |
| WO2013169218A1 (en) | Pharmaceutical compositions of s-etodolac | |
| JP2016175865A (en) | Tablet containing irbesartan with improved chemical stability | |
| WO2011055375A1 (en) | Bioequivalent formulation of efavirenz |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09843945 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 7687/CHENP/2011 Country of ref document: IN |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 09843945 Country of ref document: EP Kind code of ref document: A1 |